MolecuLightDX

by MolecuLight  · Based in Canada →Start Seeing Wounds in a New Light
Dermatology Infectious Disease Plastic Surgery

Documentation ProvidedRegulatory Status Disclosed

Overview

The MolecuLightDX™ is an advanced fluorescence imaging device designed for point-of-care detection of elevated bacterial burden in wounds. This innovative tool provides clinicians with real-time visualization of bacteria, enabling more informed clinical decision-making to improve wound healing rates.

By using the MolecuLightDX, physicians can identify the presence and location of bacteria in wounds that may not be clinically apparent, guiding targeted treatment strategies. This can lead to more effective debridement, antimicrobial therapy, and overall wound management, potentially reducing the need for broad-spectrum antibiotics and improving patient outcomes.

The device is part of MolecuLight’s product suite, which also includes the MolecuLight i:X, offering similar capabilities along with digital wound area measurement. Both devices are designed to seamlessly integrate into existing wound care workflows, providing a non-invasive, real-time assessment tool that can be used in various clinical settings.

MolecuLight emphasizes the potential for cost savings and improved patient outcomes through the use of their technology. The MolecuLightDX is supported by clinical research and offers comprehensive EMR integration, aiming to streamline documentation and enhance the utility of the device within a practice’s existing infrastructure. The company is SOC 2 accredited, underscoring its commitment to data security and privacy.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Real-time fluorescence imaging of bacteria
  • Point-of-care detection of elevated bacterial burden
  • Non-invasive wound assessment
  • Guides targeted treatment decisions
  • Comprehensive EMR integration
  • Improved wound healing rates
  • Reduced need for broad-spectrum antibiotics
  • Digital wound area measurement (with i:X)
  • Telemedicine solution compatibility

Use Cases

  • Identifying bacterial presence in chronic wounds
  • Guiding debridement procedures
  • Optimizing antimicrobial therapy selection
  • Monitoring wound healing progress
  • Informing clinical decision-making in wound care
  • Enhancing documentation through EMR integration

What Physicians Need to Know

Evidence Base
The MolecuLightDX is supported by an extensive body of clinical evidence, including over 80 peer-reviewed publications involving 2,500 patients. It is an FDA-cleared Class II medical device for real-time detection and visualization of elevated bacterial loads (>10u2074 CFU/g) in wounds using fluorescence imaging. The device's wound measurement function has also been qualified by the FDA as a Medical Device Development Tool (MDDT), indicating its scientific validation for use in medical device development and evaluation. The technology is included in the ISWCAP 2022 Consensus Guidelines for Optimizing Prevention of Surgical Wound Complications and a Delphi Consensus was created to establish guidelines on fluorescence imaging of bacterial burden.
Clinical Validation Studies
The MolecuLightDX has undergone clinical validation studies demonstrating its accuracy and reproducibility for wound surface area and depth measurements, showing superior accuracy compared to conventional ruler-based methods. One study showed a mean percentage error for surface area of <10%, a tenfold improvement over ruler estimation (77.9%). Intra- and inter-user variability for wound area was <10% and for depth, ICCs were u22480.99. A prospective, paired, multicenter clinical study compared MolecuLightDX measurements with ruler methods against an image-based ground truth. Its performance is supported by the largest clinical validation study in wound imaging, demonstrating consistent results across wound types, skin tones, and patient populations. Studies have shown that using MolecuLight to inform wound care leads to 2x more wounds healed by 12 weeks and 79% greater reduction in wound area by 12 weeks when harmful bacteria are removed. It also significantly improved the detection of high bacterial loads across all skin tones over standard of care.
Alert Fatigue Management
The MolecuLightDX provides real-time data by visualizing bacterial presence, guiding more precise treatment strategies and helping clinicians effectively target areas for cleansing, debridement, and sampling. This direct visual information at the point of care may reduce the reliance on less specific indicators, potentially mitigating alert fatigue associated with ambiguous or non-actionable alerts.
Differential Diagnosis Support
The device helps differentiate certain bacterial species, such as *Pseudomonas aeruginosa*, which is detected through cyan fluorescence. This precise bacterial identification allows for more targeted treatments.
Clinical Workflow Integration
The MolecuLightDX is designed for seamless integration into clinical workflows. It is handheld, portable, and lightweight, making it easy to move between rooms or departments. Its intuitive interface and touch-screen functionality improve the efficiency of wound care assessments. It offers patient-centric data organization, tracking images by patient and wound over time, including wound size and fluorescence differences. The device also features stickerless digital wound measurement, automatically capturing wound dimensions without physical markers.
Decision Audit Trail
The MolecuLightDX allows for effortless tracking and storage of wound images and details, providing comprehensive evidence-based documentation to monitor changes in wound bioburden, treatment effectiveness, and wound healing over time. The device has successfully completed SOC 2u00ae Type I and Type II audits, demonstrating its commitment to data security, availability, and confidentiality, including how the devices manage customer and user data, as well as security policies and procedures.
Physician Tip

Utilize the real-time bacterial fluorescence imaging to guide targeted wound cleansing, debridement, and sampling, especially in wounds lacking overt clinical signs of infection. Pay close attention to cyan fluorescence, which specifically indicates the presence of *Pseudomonas aeruginosa*, allowing for tailored antimicrobial strategies. Integrate the digital wound measurement feature to accurately track wound progression and assess treatment efficacy over time. Leverage the EMR integration to streamline documentation and ensure comprehensive patient records. Remember that while the device identifies elevated bacterial loads, it should be used in conjunction with clinical signs and symptoms and does not rule out the presence of bacteria or diagnose/treat wounds.

The MolecuLightDX offers comprehensive EMR/EHR integration options and supports integration with most EMR platforms. It is available on the Epic App Market, allowing wireless transfer of standard, fluorescence, and measurement images to the Epic EMR patient record. Direct integrations are also available with DrChrono, ModMed, Net Health (via Tissue Analytics), Intellicure, and DocNow, enabling automatic and seamless upload of wound images and data to the respective EHR platforms. These integrations often include features like secure single sign-on, automatic download of scheduled patients, and Wi-Fi-enabled automatic upload of data, with offline functionality for mobile care providers.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics, Radiology & Imaging AI
Pricing Unknown unknown
Free Trial No
DeploymentOn-premise device
Mobile AppNone
Data ExportUnknown
LanguagesEnglish
TrainingUnknown
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated — The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.
SOC 2 Yes AI-estimated
Integrations
EHR Not specified
Specialties Dermatology, Infectious Disease, Plastic Surgery

Social Proof

Customersunknown
Notable
unknown

Support & Reliability

Training ProvidedUnknown

What the Web Says

The MolecuLightDX is a point-of-care fluorescence imaging device that allows for real-time detection of elevated bacterial burden in wounds, often undetectable by visual inspection. It also provides accurate digital wound measurement and, with a new module, thermal imaging. Physicians generally view it as a valuable tool that informs treatment decisions, improves wound healing rates, and enhances documentation.

Overall: Positive

Strengths

  • Real-time detection of elevated bacterial burden in wounds, even when asymptomatic.
  • Informs clinical decision-making, leading to changes in treatment plans and improved patient outcomes.
  • Accurate, rapid digital wound measurement for documentation and tracking wound progression.
  • Comprehensive electronic medical record (EMR) integration options.
  • Patient-centric user interface and workflow for easy patient and wound tracking.
  • Optional Thermal Imaging Module for a more comprehensive understanding of the wound environment.

Limitations

  • Some sources indicate that the evidence base for the device, while growing, has been of low methodological quality, lacking randomized controlled trials, meta-analyses, or systematic reviews in the past.
  • One review from Indeed.com for the company MolecuLight (not specifically the DX device) mentions a stressful work environment, unprofessional management, and unreasonable workload.
  • General review platforms like G2 and Capterra, while useful for software, did not have specific reviews for MolecuLightDX, but rather for their own platforms or other unrelated 'DX' software.

Based on reviews from: Lower Extremity Review Magazine, MolecuLight (Official Website), WoundSource, Molina Healthcare, Indeed.com, DrChrono, Team Medical

Last updated: 2026-08-24

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MolecuLightDX

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
FDA Qualifies MolecuLightDX Wound Measurement as a Medical Device Development Tool (MDDT) for Evaluating New Products in Wound Care
MolecuLight announced that its MolecuLightDX wound measurement has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT), allowing its use as a standardized, trusted measurement tool in wound healing studies.
2026-01
OEM News
MolecuLightDX Wound Measurement Deemed a Medical Device Development Tool by FDA
The FDA has qualified MolecuLightDX's quantitative wound measurement function as a Medical Device Development Tool (MDDT), validating its use as a response biomarker for regulatory purposes.
2026-03
Press Release Hub
MolecuLight Showcases 10 Scientific Posters at SAWC Fall and Announces Upcoming Oxygenation Imaging on the MolecuLightDXu00ae+ Platform
MolecuLight announced plans to expand its MolecuLightDX+ imaging platform to include oxygenation imaging, aiming to provide comprehensive wound care imaging from a single handheld system with FDA submission expected in Q4 2025.
2025-09
PR Newswire
MolecuLightDXu00ae Now Available on Oracle Healthcare Marketplace
MolecuLightDX is now available on the Oracle Healthcare Marketplace, enabling direct integration with the Oracle Health Foundation electronic health record (EHR) for streamlined wound documentation.
2025-12
PR Newswire
MolecuLightDXu00ae Integration Now Available on ModMed Marketplace
The MolecuLightDX is now integrated with ModMed's Electronic Health Record (EHR) platform via the ModMed Marketplace, allowing for seamless transfer of wound images and data.
2026-07
MDPI (Diagnostics)
Accuracy and Reproducibility of Digital Area and Depth Measurements of Surface Wounds: Benchtop and Clinical Validation
This peer-reviewed study evaluated the accuracy and reproducibility of the MolecuLightDX wound imaging device for surface area and depth measurements, highlighting its potential for standardized digital wound assessment.
2026-04
PR Newswire
Auto Depth Digital Wound Measurement Now Available on MolecuLightDX
MolecuLight announced that its MolecuLightDXu2122 device now features automatic wound depth measurement, providing a complete digital wound measurement solution without the need for calibration stickers.
2024-10
PR Newswire
MolecuLightDXu2122 Wins Award as a Top Innovation in Wound Care 2022 From Wound Management & Prevention Journal
MolecuLightDXu2122 received a 'Top Innovation in Wound Care 2022' Award from Wound Management & Prevention Journal for its ability to provide point-of-care detection of elevated bacterial burden in wounds.
2022-07

Videos

Product demos, reviews, and walkthroughs for MolecuLightDX.

Loading videos...

View all on YouTube

No FAQs available yet for this tool.

Related Tools

OCTA
OCTA
Clinical Decision Support & Reference
OCTA Flow is an AI-powered platform that assists ophthalmologists in analyzing Optical Coherence Tomography Angiography (OCTA) scans to enhance diagnostic accuracy and efficiency.
Elsevier
Elsevier
Clinical Decision Support & Reference
ClinicalKey AI is a clinical decision support tool that uses artificial intelligence to provide physicians with rapid access to evidence-based medical information.
EvidenceMD
EvidenceMD
Clinical Decision Support & Reference
EvidenceMD is an AI-powered clinical decision support platform that provides physicians with rapid access to current and relevant medical evidence for informed decision-making.
FAITH project
AI Agent
Clinical Decision Support & Reference
The FAITH project focuses on Federated Artificial Intelligence for Trusted Healthcare, aiming to develop secure and privacy-preserving AI solutions for healthcare, including potential applications for physician directories.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
Prof. Valmed
Prof. Valmed - validated medical information GmbH
Clinical Decision Support & Reference
Prof. Valmed is Europe's first CE Class IIb certified AI-supported medical co-pilot, providing healthcare professionals with validated, evidence-based medical information through an innovative AI platform.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-08-23 | First Added: 2026-08-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.